TP53 codon 72 polymorphism may predict early tumour progression in paediatric pilocytic astrocytoma

Oncotarget. 2016 Jul 26;7(30):47918-47926. doi: 10.18632/oncotarget.10295.

Abstract

Pilocytic astrocytoma and ganglioglioma may occur in inaccessible or surgically difficult areas. In case of incomplete resection, the availability of biological predictors of tumour progression could be particularly important. To this end, an analysis of p53 codon 72 polymorphism and assessment of its role as prognostic marker were performed.The status of the p53 Arg72Pro polymorphism was evaluated by pyrosequencing method in a multicenter cohort of 170 paediatric patients. Genotype/phenotype associations were investigated either by means of bivariate or multivariate analyses.In the partially resected pilocytic astrocytomas, the Arg/Arg variant predicts early tumour progression (median survival time: 23.1 months) and is associated with poor event-free survival (p value = 0.0009). This finding remains true also in case of adjuvant therapies, with a 5-year event-free survival of 30.6% for cases with Arg/Arg variant vs. 78.7% for those with other genotypes. There is no association between ganglioglioma and the polymorphism.The assessment of Arg/Arg variant could improve the management of pilocytic astrocytoma. TP53 codon 72 analysis could distinguish low-risk cases, in which surgery could be conservative, from high-risk cases needing an aggressive surgery plan.

Keywords: TP53; low-grade gliomas; paediatric; pilocytic astrocytoma; polymorphism.

MeSH terms

  • Adolescent
  • Astrocytoma / genetics*
  • Astrocytoma / pathology
  • Brain Neoplasms / genetics*
  • Brain Neoplasms / pathology
  • Child
  • Child, Preschool
  • Cohort Studies
  • Disease Progression
  • Female
  • Humans
  • Infant
  • Male
  • Polymorphism, Single Nucleotide
  • Survival Analysis
  • Tumor Suppressor Protein p53 / genetics*

Substances

  • TP53 protein, human
  • Tumor Suppressor Protein p53